1. Yang, Zhen, Liu, Xinpeng, Zhu, Jun, Fu, Li, Cao, Xuetao. 2024. Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1. In Cancer cell, 43, 86-102.e10. doi:10.1016/j.ccell.2024.11.008. https://pubmed.ncbi.nlm.nih.gov/39672166/
2. Li, Bowen, Liu, Jiang, Huang, Ling, Liu, Zhaohui, Liu, Tiande. 2024. SNRPB2 in the pan-cancer landscape: A bioinformatics exploration and validation in hepatocellular carcinoma. In Cellular signalling, 124, 111445. doi:10.1016/j.cellsig.2024.111445. https://pubmed.ncbi.nlm.nih.gov/39366532/
3. Deng, Mingyang, Yuan, Huan, Peng, Hongling, Zhang, Guangsen, Xiao, Han. . LINC00461 Knockdown Enhances the Effect of Ixazomib in Multiple Myeloma Cells. In Current cancer drug targets, 23, 643-652. doi:10.2174/1568009623666230316152713. https://pubmed.ncbi.nlm.nih.gov/36927430/
4. Yu, Shiyi, Si, Yue, Yu, Jianzhong, Bi, Caili, Sun, Haibo. 2024. SNRPB2 promotes triple-negative breast cancer progression by controlling alternative splicing of MDM4 pre-mRNA. In Cancer science, 115, 3915-3927. doi:10.1111/cas.16356. https://pubmed.ncbi.nlm.nih.gov/39329452/
智鼠故事 
